Insider Selling: Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Sells 10,000 Shares of Stock

Sensus Healthcare, Inc. (NASDAQ:SRTSGet Rating) Director William H. Mccall sold 10,000 shares of Sensus Healthcare stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $7.54, for a total value of $75,400.00. Following the sale, the director now owns 325,723 shares of the company’s stock, valued at $2,455,951.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ SRTS opened at $8.52 on Friday. The business has a fifty day moving average price of $9.22 and a 200 day moving average price of $8.03. Sensus Healthcare, Inc. has a one year low of $3.08 and a one year high of $11.96. The company has a market cap of $142.11 million, a P/E ratio of 6.66 and a beta of 0.52.

Sensus Healthcare (NASDAQ:SRTSGet Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.91. Sensus Healthcare had a return on equity of 38.23% and a net margin of 62.07%. During the same quarter in the previous year, the firm posted ($0.07) earnings per share. On average, research analysts predict that Sensus Healthcare, Inc. will post 0.76 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. Dorsey Wright & Associates acquired a new stake in Sensus Healthcare in the 1st quarter valued at about $54,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Sensus Healthcare by 83.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 5,500 shares of the company’s stock worth $40,000 after acquiring an additional 2,500 shares in the last quarter. HCR Wealth Advisors acquired a new stake in shares of Sensus Healthcare during the 4th quarter worth about $72,000. AE Wealth Management LLC acquired a new stake in shares of Sensus Healthcare during the 1st quarter worth about $192,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Sensus Healthcare during the 4th quarter worth about $141,000. Institutional investors own 20.49% of the company’s stock.

Several analysts recently weighed in on the company. HC Wainwright lifted their price objective on Sensus Healthcare from $12.00 to $13.00 and gave the company a “buy” rating in a report on Thursday, March 3rd. TheStreet upgraded Sensus Healthcare from a “c” rating to a “b-” rating in a research note on Friday, February 11th. Zacks Investment Research upgraded Sensus Healthcare from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a research note on Thursday. Finally, Maxim Group reiterated a “buy” rating and issued a $14.00 target price on shares of Sensus Healthcare in a research report on Friday, May 6th.

About Sensus Healthcare (Get Rating)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Read More

Insider Buying and Selling by Quarter for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.